ASHM @ CROI 2014
ASHM Members @ CROI 2014
|
Report-back postsNeuroHIV in 2014: Beyond dementia
Serena Spudich presented information about HIV infection causing ongoing active injury to the central nervous system (CNS) - comprising the b
HIV Incidence Assays
The discussion generated by this, quite complex topic, was stimulating. CDC reported that a dried blood spot sample gave comparable performance to
Is Vitamin D for everyone initiating ART?
Supplementing starters on ART containing Efavirenz and Tenofovir with 4000 iu Vit D, and oral calcium, reduced BMD loss by 50% in the first year,
Underestimating resistance in transmitted HIV
Jeffrey Johnston from CDC Atlanta presented results of highly sensitive resistance testing showing transmitted resistance in 16%, rather than the
PrEP now and in the future
Many presentations pushed the need to get going now with oral PrEP for it's already proven benefit, even though what we have isn't perfect, isn't
Safety of condomless sex
A much anticipated late breaking presentation from London was a study looking at transmission from people with Viral Loads less than 200, who practi
Fascinating presentations on the role of early ART treatment, T cell and tissue reservoirs for HIV, and the role of inflammation in HIV infection
Katherine Luzuriaga presented data showing that early cART (initiation before 6 weeks of age) leads to a restricted latent reservoir of HIV, and a
Promise is being shown in accessing reservoirs that cause persistence of HIV infection and finding ways to eliminate HIV in latently infected cells
HIV-1 infection and Type-1 interferon
The interaction of HIV-1 and Type-1 Interferon (IFN-1) is complex. High levels of IFN-1 during acute HIV in
Novel PrEP delivery
Injectable GSK744 LA (long acting) is an analogue of Dolutegravir currently undergoing trials as a potential PrEP agent. Abstracts #39 and #40LB
Update on HPV vaccines and early ART initiation in infants
HPV Vaccines: Progress to date and future worldwide directions – Abstract #19
Douglas R. Lowy presented on current effects of HPV vaccination and
Burden of of illicit drug use and benefits of early ART
Illicit drug use and HIV
Adeeba Kamarulzaman from Malaysia presented on HIV in people who inject drugs (PWID). Due to time constrains, PrEP
First impressions of CROI 2014
Hi. I'm Ken Hazelton, a GP S100 prescriber from Orange NSW, and the grateful recipient of an ASHM scholarship to CROI, Boston 2014. HIV is i
PrEP: Use it or lose it
David Bangsberg, Abstract #7 was a thorough discussion on the impact of adherence problems in the PrEP studies. He discussed complicated issue
Early reflections on CROI 2014
Hong-Ha Troung, presented more data from San Francisco characterising new HIV infections. STIs remain a significant cofactor in new infect
CROI Day 1: Bernard Fields Lecture
Attending my first CROI in Boston, I am amazed by two things. Firstly, how cold it is during the day. I'm sure my eyeballs were going to freeze walkin
|